Uromitexan 100 mg/ ml Norge - norsk - Statens legemiddelverk

uromitexan 100 mg/ ml

baxter medical ab - mesna - injeksjonsvæske, oppløsning - 100 mg/ ml

Uromitexan 600 mg Norge - norsk - Statens legemiddelverk

uromitexan 600 mg

baxter medical ab - mesna - tablett, filmdrasjert - 600 mg

Vinelle 75 mikrog Norge - norsk - Statens legemiddelverk

vinelle 75 mikrog

campuspharma ab - desogestrel - tablett - 75 mikrog

Yasminelle 0.02 mg / 3 mg Norge - norsk - Statens legemiddelverk

yasminelle 0.02 mg / 3 mg

bayer ab - solna - etinyløstradiolbetadeksklatrat / drospirenon - tablett, filmdrasjert - 0.02 mg / 3 mg

Drovelis Den europeiske union - norsk - EMA (European Medicines Agency)

drovelis

gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - sex hormoner og modulatorer av genital systemet, - oral contraceptive.

Naiwanel 0.02 mg / 3 mg Norge - norsk - Statens legemiddelverk

naiwanel 0.02 mg / 3 mg

medical valley - etinyløstradiol / drospirenon - tablett, filmdrasjert - 0.02 mg / 3 mg

Naiwanel 28 0.02 mg / 3 mg Norge - norsk - Statens legemiddelverk

naiwanel 28 0.02 mg / 3 mg

medical valley - etinyløstradiol / drospirenon - tablett, filmdrasjert - 0.02 mg / 3 mg

Atlantis OD Norge - norsk - myHealthbox

atlantis od

bayer ag -

Amorina 0.25 mg / 0.035 mg Norge - norsk - Statens legemiddelverk

amorina 0.25 mg / 0.035 mg

effik s.a - norgestimat / etinyløstradiol - tablett - 0.25 mg / 0.035 mg

Pylclari Den europeiske union - norsk - EMA (European Medicines Agency)

pylclari

curium pet france - piflufolastat (18f) - prostata neoplasmer - diagnostiske radiopharmaceuticals - dette legemidlet er kun til diagnostisk bruk. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).